[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Clinical efficacy of ribavirin in the treatment of genital herpes simplex virus infection

Chemotherapy. 1981;27(2):139-45. doi: 10.1159/000237969.

Abstract

48 patients participated in a double-blind placebo-controlled study conducted to evaluate the efficacy of ribavirin in the treatment of herpes simplex virus genital infection. Study design did not allow a conclusion regarding usefulness of the drug in preventing recurrences. Ribavirin treatment (800 mg/day p.o) for 10 days reduced disease severity and promoted recovery as compared with placebo treatment.

Publication types

  • Clinical Trial

MeSH terms

  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Herpes Simplex / drug therapy*
  • Humans
  • Male
  • Placebos
  • Ribavirin / adverse effects
  • Ribavirin / therapeutic use*
  • Ribonucleosides / therapeutic use*

Substances

  • Placebos
  • Ribonucleosides
  • Ribavirin